MedTrace Logo

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

NCT05718700 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2025-11-17

No results posted yet for this study

Summary

The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.

Conditions

  • Chronic Hepatitis D Infection

Interventions

DRUG

Bulevirtide

Administered via subcutaneous (SC) injections

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-07
Primary Completion
2028-07-31
Completion
2028-07-31
FDA Drug
Yes

Countries

  • Austria
  • France
  • Germany
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718700 on ClinicalTrials.gov